Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about LRP1 receptor-mediated transcytosis: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| LRP1-Dependent Tau Uptake Disruption | 0.796 | neurodegeneration | Tau propagation mechanisms and therapeut |
| Synthetic Biology BBB Endothelial Cell Reprogramming | 0.645 | neurodegeneration | Blood-brain barrier transport mechanisms |
| Circadian-Synchronized LRP1 Pathway Activation | 0.610 | neurodegeneration | Blood-brain barrier transport mechanisms |
| LRP1-Dependent Tau Uptake Disruption | 0.532 | Alzheimer's Disease | Tau propagation mechanisms and therapeut |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.657
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Vascular Contribution to Alzheimer's Disease — Beyond Amyloid | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| Blood-Based Biomarker Panel for Early AD Detection | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $220,000 |
| Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neur | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $130,000 |
| s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $200,000 |
| s:** - Compare uptake with/without magnetic particles using tight junc | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $120,000 |
| Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy in 4R-Tau | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $170,000 |
| Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauopathy | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Tau Spreading Network Mapping via Spatial Transcriptomics in PSP | clinical | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $520,000 |
| 4R-Tau Targeting Therapies for PSP and CBS | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Tau Propagation Causality Test — Does Tau Spread Drive Neurodegenerati | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omics Study | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| Tau Pathology Initiation Zone Identification | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| PSP and CBS Biomarker Validation Study | clinical | ALS | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have N | clinical | ALS | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Blood Biomarker vs Tau PET for Treatment Monitoring | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmon [PMID:35257044] | Calvier L, Herz J, Hansmann G | JACC Basic Transl Sci | 2022 | 1 |
| Modulating LRP1 Pathways in Alzheimer's Disease: Mechanistic Insights and Emergi [PMID:41772271] | Mushtaq T, Hameed H, Khan MA, Tariq U, H | Molecular neurobiology | 2026 | 0 |
| Insulin-like growth factor-1 enhances β-amyloid protein clearance in HMC3 microg [PMID:41621577] | Guo H, Peng X, Zhang X, Ruganzu JB, Wu X | Experimental cell research | 2026 | 0 |
| Osteoclast-secreted galectin-3 promotes articular cartilage degeneration in OVX [PMID:40609733] | Chen L, Hong H, Yang Z, Zhong Y, Sun S e | Osteoarthritis Cartilage | 2026 | 0 |
| Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses [PMID:41927877] | Miao J, Wang J, Zhou W, Guo J | Sci Rep | 2026 | 0 |
| Targeting the HDAC4-NHE6-endosomal pH axis restores amyloid-β clearance and cogn [PMID:41933339] | Huang N, Hong R, Cui X, Cao L, Shi L et | J Nanobiotechnology | 2026 | 0 |
| Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR [PMID:41934727] | Li D, Zhang Y, Wang R, Jin L, Cui X et a | Neurotherapeutics | 2026 | 0 |
| Brain and Liver Dual-Targeting Oridonin Nanoparticles to Enhance Aβ Clearance fo [PMID:41944296] | Gong W, Hui W, Qiao S, Ji Q, Liu M et al | Adv Sci (Weinh) | 2026 | 0 |
| Efficient amyloid-β degradation in Alzheimer's disease using SPYTACs. [PMID:41785850] | Teng F, Liu J, Cui T, Tan X, Liu K, Hou | Cell | 2026 | 0 |
| Lysosomal trafficking markers covering PSAP, PGRN, SORT1 and LRP1 in body liquid [PMID:41579784] | Poniatowski ŁA, Siwińska A, Acewicz A, K | Forensic science international | 2026 | 0 |
| Mitochondrial calcium uniporter knockdown in hippocampal neurons effectively att [PMID:41687804] | Wu L, Hou F, Wang Z, Wu M, Wang X, Cao J | Experimental neurology | 2026 | 0 |
| ROS-responsive nanogels for brain targeted delivery of icariin in the treatment [PMID:41197818] | ["Li X", "Huang J", "Zhou Y", "Chen X", | International journal of pharm | 2026 | 0 |
| Integrative bioinformatics frameworks for abdominal aortic aneurysm using GWAS m [PMID:40595262] | Sagulkoo P, Chuntakaruk H, Suratanee A, | Scientific reports | 2025 | 0 |
| Inhibition of tau neuronal internalization using anti-tau single domain antibodi [PMID:40175345] | ["Danis C", "Dupr\u00e9 E", "Bouillet T" | Nature communications | 2025 | 0 |
| Schwann cell Lrp1 deletion drives trigeminal neuron sensitization and orofacial [PMID:41430102] | Gong Z, Zhang M, Liu N, Asam K, Martellu | The journal of headache and pa | 2025 | 0 |
| Ganglioside sialylation modulates tau internalization and pathology spread. [PMID:41398374] | Li S, Chen Y, Song T, Liu D, Wu R, Yang | Molecular psychiatry | 2025 | 0 |
| Microglia internalize tau monomers and fibrils using distinct receptors but simi [PMID:39713861] | Falkon KF, Danford L, Gutierrez Kuri E, | Alzheimer's & dementia : the j | 2025 | 0 |
| Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next- [PMID:41199078] | ["Ranjitha V", "Kumar A", "Kaalappa P"] | Pharmaceutical research | 2025 | 0 |
| Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746] | ["Sanadgol N", "Abedi M", "Hashemzaei M" | Journal of nanobiotechnology | 2025 | 0 |
| Astrocytic LRP1 enables mitochondria transfer to neurons and mitigates brain isc [PMID:38906140] | Zhou J, Zhang L, Peng J, Zhang X, Zhang | Cell metabolism | 2024 | 0 |
Multi-agent debates referencing this entity